Ani Pharmaceuticals CEO and leadership

Nikhil Lalwani is a Board Member at ANI PHARMACEUTICALS INC and President/CEO at ANI PHARMACEUTICALS INC. He has worked as Chief Executive Officer at Cipla USA Inc.. Nikhil studied at Georgia Tech and The Wharton School.

Mr. Walsh has been a member of the Board since May 2019. He is President & Managing Member of Diligence Team and Diligence Group LLC, consulting practices he founded and is based in Durham, North Carolina and brings over 35 years of experience in the pharmaceutical industry. From May 2019 to April 2020, He was co-founder and CEO of TriPharm Services, an injectable manufacturing business which was acquired by Alcami. From 2015 to February 2019, Mr. Walsh was the chief executive officer of Avista Pharma, a private equity backed global provider of contract manufacturing, development and analytical testing services to pharmaceutical and biotechnology clients that was acquired by Cambrex. Prior to Avista, from 2010 to 2014, Mr. Walsh was the chief executive officer of AAIPharma Services Corporation in Wilmington, North Carolina, a private equity backed global provider of contract manufacturing services. Mr. Walsh’s earlier career includes serving as chief executive officer of Kadmus Pharmaceuticals, Inc., in Irvine, California, and serving as president and chief operating officer of publicly-traded Gensia-Sicor Pharmaceuticals, Inc which was acquired by Teva for $3.2 billion. Mr. Walsh currently serves as an independent director of the Board of Directors of Avid Bioservices, a publicly-traded company based in Tustin, California and serves on its corporate governance committee and is chair of the compensation committee. He is also an independent director of the Board of Directors of Institute Chemica Emiliano (I.C.E.), a privately held specialty chemical company based in Milan Italy. He is also an Operating Partner (part-time) to healthcare private-equity firm Ampersand Capital, based in Wellesley, Massachusetts.

Senior finance executive with record of partnering with cross-functional business leaders in delivering exceptional results while actively managing complex finance and accounting environments. Recognized as an impactful leader successful at building high performance teams in periods of growth and adversity. Combines broad business perspectives with seasoned accounting and finance skills to build trust with internal and external clients. Highly effective at communicating complex financial information to a diverse set of constituents, including C-suite, Board of Directors, Wall Street analysts, investment banks, business partners, auditors and attorneys.

Currently, Vice President and CFO of ANI Pharmaceuticals (NASDAQ: ANIP), a rapidly growing generic and specialty pharmaceutical company.

Previously, critical member of executive management team responsible for driving an 8X return in three year period in highly successful public / private / strategic sale transaction for Par Pharmaceutical (the fifth largest U.S. generic pharmaceuticals company) and TPG (global private equity firm with $70B of capital under management).

Also has extensive experience in operational finance roles at a Fortune 250 multinational corporation and strong public accounting foundation with premier Big-4 accounting firm.

Core skills include:

• Executive level strategic support

• M&A and BD; including diligence, modeling, valuation, contract review and negotiations

• Strategic sale / contractual negotiation support

• S-1 / Initial Public Offering (IPO) process

• Controllership; including accounting, analysis, revenue recognition, tax and SEC compliance

• Management, PE Sponsor, BOD, and Bank reporting

• Financial and strategic business planning and analysis / forecasting

• International finance / operations support

• Debt compliance

• Manufacturing, marketing and R&D finance

• Investor relation support

• Strategic alliance management

• Legal negotiations and settlements

Chris Mutz is a Chief Commercial Officer/Head:Rare Diseases at ANI PHARMACEUTICALS INC. He has worked as VP:Neurology Business US at ANI PHARMACEUTICALS INC. Chris attended University of Virginia and Cornell.

Nikhil Lalwani is a Board Member at ANI PHARMACEUTICALS INC and President/CEO at ANI PHARMACEUTICALS INC. He has worked as Chief Executive Officer at Cipla USA Inc.. Nikhil studied at Georgia Tech and The Wharton School.

Mr. Walsh has been a member of the Board since May 2019. He is President & Managing Member of Diligence Team and Diligence Group LLC, consulting practices he founded and is based in Durham, North Carolina and brings over 35 years of experience in the pharmaceutical industry. From May 2019 to April 2020, He was co-founder and CEO of TriPharm Services, an injectable manufacturing business which was acquired by Alcami. From 2015 to February 2019, Mr. Walsh was the chief executive officer of Avista Pharma, a private equity backed global provider of contract manufacturing, development and analytical testing services to pharmaceutical and biotechnology clients that was acquired by Cambrex. Prior to Avista, from 2010 to 2014, Mr. Walsh was the chief executive officer of AAIPharma Services Corporation in Wilmington, North Carolina, a private equity backed global provider of contract manufacturing services. Mr. Walsh’s earlier career includes serving as chief executive officer of Kadmus Pharmaceuticals, Inc., in Irvine, California, and serving as president and chief operating officer of publicly-traded Gensia-Sicor Pharmaceuticals, Inc which was acquired by Teva for $3.2 billion. Mr. Walsh currently serves as an independent director of the Board of Directors of Avid Bioservices, a publicly-traded company based in Tustin, California and serves on its corporate governance committee and is chair of the compensation committee. He is also an independent director of the Board of Directors of Institute Chemica Emiliano (I.C.E.), a privately held specialty chemical company based in Milan Italy. He is also an Operating Partner (part-time) to healthcare private-equity firm Ampersand Capital, based in Wellesley, Massachusetts.